Prognostic implications of the expression levels of different immunoglobulin heavy chain-encoding RNAs in early breast cancer
Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift
Standard
Prognostic implications of the expression levels of different immunoglobulin heavy chain-encoding RNAs in early breast cancer. / Larsson, Christer; Ehinger, Anna; Winslow, Sofia; Leandersson, Karin; Klintman, Marie; Dahl, Ludvig; Vallon-christersson, Johan; Häkkinen, Jari; Hegardt, Cecilia; Manjer, Jonas; Saal, Lao; Rydén, Lisa; Malmberg, Martin; Borg, Åke; Loman, Niklas.
I: npj Breast Cancer, Vol. 6, Nr. 1, 28, 06.07.2020.Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift
Harvard
APA
CBE
MLA
Vancouver
Author
RIS
TY - JOUR
T1 - Prognostic implications of the expression levels of different immunoglobulin heavy chain-encoding RNAs in early breast cancer
AU - Larsson, Christer
AU - Ehinger, Anna
AU - Winslow, Sofia
AU - Leandersson, Karin
AU - Klintman, Marie
AU - Dahl, Ludvig
AU - Vallon-christersson, Johan
AU - Häkkinen, Jari
AU - Hegardt, Cecilia
AU - Manjer, Jonas
AU - Saal, Lao
AU - Rydén, Lisa
AU - Malmberg, Martin
AU - Borg, Åke
AU - Loman, Niklas
PY - 2020/7/6
Y1 - 2020/7/6
N2 - The extent and composition of the immune response in a breast cancer is one important prognostic factor for the disease. The aim of the current work was to refine the analysis of the humoral component of an immune response in breast tumors by quantifying mRNA expression of different immunoglobulin classes and study their association with prognosis. We used RNA-Seq data from two local population-based breast cancer cohorts to determine the expression of IGJ and immunoglobulin heavy (IGH) chain-encoding RNAs. The association with prognosis was investigated and public data sets were used to corroborate the findings. Except for IGHE and IGHD, mRNAs encoding heavy chains were generally detected at substantial levels and correlated with other immune-related genes. High IGHG1 mRNA was associated with factors related to poor prognosis such as estrogen receptor negativity, HER2 amplification, and high grade, whereas high IGHA2 mRNA levels were primarily associated with lower age at diagnosis. High IGHA2 and IGJ mRNA levels were associated with a more favorable prognosis both in univariable and multivariable Cox models. When adjusting for other prognostic factors, high IGHG1 mRNA levels were positively associated with improved prognosis. To our knowledge, these results are the first to demonstrate that expression of individual Ig class types has prognostic implications in breast cancer.
AB - The extent and composition of the immune response in a breast cancer is one important prognostic factor for the disease. The aim of the current work was to refine the analysis of the humoral component of an immune response in breast tumors by quantifying mRNA expression of different immunoglobulin classes and study their association with prognosis. We used RNA-Seq data from two local population-based breast cancer cohorts to determine the expression of IGJ and immunoglobulin heavy (IGH) chain-encoding RNAs. The association with prognosis was investigated and public data sets were used to corroborate the findings. Except for IGHE and IGHD, mRNAs encoding heavy chains were generally detected at substantial levels and correlated with other immune-related genes. High IGHG1 mRNA was associated with factors related to poor prognosis such as estrogen receptor negativity, HER2 amplification, and high grade, whereas high IGHA2 mRNA levels were primarily associated with lower age at diagnosis. High IGHA2 and IGJ mRNA levels were associated with a more favorable prognosis both in univariable and multivariable Cox models. When adjusting for other prognostic factors, high IGHG1 mRNA levels were positively associated with improved prognosis. To our knowledge, these results are the first to demonstrate that expression of individual Ig class types has prognostic implications in breast cancer.
U2 - 10.1038/s41523-020-0170-2
DO - 10.1038/s41523-020-0170-2
M3 - Article
C2 - 32656317
VL - 6
JO - npj Breast Cancer
JF - npj Breast Cancer
SN - 2374-4677
IS - 1
M1 - 28
ER -